Literature DB >> 23402476

Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension.

Takafumi Okura1, Ken-ichi Miyoshi, Jun Irita, Daijiro Enomoto, Masanori Jotoku, Tomoaki Nagao, Kouki Watanabe, Hiroshi Matsuoka, Toshiaki Ashihara, Jitsuo Higaki.   

Abstract

Left ventricular hypertrophy (LVH) regression is an important issue in hypertensive patients. Patients with LVH who had received the angiotensin receptor blocker (ARB) treatment for 8 weeks and had not reached the target blood pressure level were enrolled in the study. Patients were assigned to either losartan (50 mg)/hydrochlorothiazide (HCTZ, 12.5 mg) group or ARB + CCB group (usual dose of ARB and calcium channel blocker, CCB). After 48 weeks, LV mass index was found to be reduced significantly in the losartan/HCTZ group but not in the ARB + CCB group. These results suggest that combination therapy of an ARB and diuretic has greater potential to cause regression compared with an ARB and CCB.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23402476     DOI: 10.3109/10641963.2013.764892

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  4 in total

1.  The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.

Authors:  Punnaka Pongpanich; Pasvich Pitakpaiboonkul; Kullaya Takkavatakarn; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

Review 2.  Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials.

Authors:  Jian-Shu Chen; Ying Pei; Cai-E Li; Yin-Ning Li; Qiong-Ying Wang; Jing Yu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-15       Impact factor: 3.738

3.  Genome-wide meta-analysis of SNP and antihypertensive medication interactions on left ventricular traits in African Americans.

Authors:  Anh N Do; Wei Zhao; Abigail S Baldridge; Laura M Raffield; Kerri L Wiggins; Sanjiv J Shah; Stella Aslibekyan; Hemant K Tiwari; Nita Limdi; Degui Zhi; Colleen M Sitlani; Kent D Taylor; Bruce M Psaty; Nona Sotoodehnia; Jennifer A Brody; Laura J Rasmussen-Torvik; Donald Lloyd-Jones; Leslie A Lange; James G Wilson; Jennifer A Smith; Sharon L R Kardia; Thomas H Mosley; Ramachandran S Vasan; Donna K Arnett; Marguerite R Irvin
Journal:  Mol Genet Genomic Med       Date:  2019-08-13       Impact factor: 2.473

4.  Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.

Authors:  Xiaoying Wang; Kai He; Linlin Ma; Lan Wu; Yan Yang; Yanfei Li
Journal:  Mol Med Rep       Date:  2022-08-10       Impact factor: 3.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.